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a  b  s  t  r  a  c  t
The  majority  of  industrialized  and  some  developing  countries  have  established  National  Immunization
Technical  Advisory  Groups  (NITAGs).  To  enable  systematic  global  monitoring  of  the  existence  and  func-
tionality  of NITAGs,  in 2011,  WHO  and UNICEF  included  related  questions  in  the  WHO/UNICEF  Joint
Reporting  Form  (JRF)  that provides  an  ofﬁcial  means  to globally  collect  indicators  of  immunization
program  performance.  These  questions  relate  to  six basic  process  indicators.
According  to  the  analysis  of  the  2013  JRF,  data  for 2012,  notable  progress  was  achieved  between  2010
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HO/UNICEF Joint Reporting Form
ational Immunization Technical Advisory
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onitoring
vidence-based decision making
and  2012  and  by  the  end  of  2012,  99 countries  (52%)  reported  the  existence  of  a NITAG  with  a  formal
legislative  or  administrative  basis  (with  a high  of  86%  in  the  Eastern  Mediterranean  Region  – EMR),  among
the  countries  that  reported  data  in  the NITAG  section  of  the  JRF.
There were  63  (33%)  countries  with  a NITAG  that met  six  process  indicators  (47%  increase  over  the
43  reported  in  2010)  including  a  total  of  38  developing  countries.  11%  of low  income  countries  reported
a  NITAG  that  meets  all six  process  criteria,  versus  29%  of  middle  income  countries  and 57%  of  the  high
Abbreviations: AFR, African Region; AMR, Region of the Americas; CDC, Centers for Disease Control and Prevention; DoV, Decade of Vaccines; EMR, Eastern Mediterranean
egion; EUR, European Region; GVAP, Global Vaccine Action Plan; JRF, Joint Reporting Form; NITAG, National Immunization Technical Advisory Group; SIVAC, Supporting
ndependent Immunization and Vaccine Advisory Committees; SEAR, South-East Asia Region; UNICEF, United Nations Children’s Fund; WHA, World Health Assembly; WHO,
orld  Health Organization; WPR, Western Paciﬁc Region.
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income  ones.  Countries  with  smaller  populations  reported  the  existence  of  a  NITAG  that  meets  all  six
process criteria  less  frequently  than  more  populated  countries  (23%  for  less  populated  countries  versus
43% for  more  populated  ones).
However, progress  needs  to  be  accelerated  to reach  the Global  Vaccine  Action  Plan  (GVAP)  target  of
ensuring all countries  have  support  from  a  NITAG.  The  GVAP  represents  a major  opportunity  to  boost  the
institutionalization of  NITAGs.  A  special  approach  needs  to  be  explored  to  allow  small  countries  to  beneﬁt
from sub-regional  or other  cou
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Notable progress was achieved between 2010 and 2012, and 99
(52%) countries overall reported the existence of a NITAG with a©
. Introduction
In May  2012, the World Health Assembly (WHA) endorsed the
ecade of Vaccines (DoV) Global Vaccine Action Plan (GVAP) [1].
nder the ﬁrst strategic objective of the plan it is stated:
“National legislation, policies and resource allocation decisions
should  be informed by credible and current evidence regard-
ing  the direct and indirect impact of immunization. Much of the
evidence  base exists but does not reach policy-makers, as those
who  generate the evidence are not always those who interact
with  these decision-makers. . . ..  Independent bodies such as
regional  or NITAGs that can guide country policies and strate-
gies  based on local epidemiology and cost effectiveness should
be  established or strengthened, thus reducing dependency on
external  bodies for policy guidance.” . . .
The existence of a NITAG is one of the critical indicators featured
n the GVAP Monitoring and Accountability Framework and each
ear a progress report including focus on the NITAGs will be dis-
ussed by the Strategic Advisory Group of Experts on Immunization
or submission to WHO  Executive Board and to the WHA  [2].
NITAGs  are aimed at guiding the formulation of national
mmunization policies and strategies to advise policy-makers and
rogramme managers on technical issues related to national immu-
ization programmes, including recommendations on vaccine
ntroduction and immunization schedules [3,4]. Their recommen-
ations should be evidence-based and generated through transpar-
nt processes [5]. Every country which has an ambition for a strong
ational immunization programme should beneﬁt from a NITAG.
Consistent  with the GVAP, WHO  and its partners place high
riority on supporting the enhancement of the capacity for
vidence-based decision making processes and the establishment
nd strengthening of functional, sustainable, and independent
ITAGs [5].
In  an effort to enable systematic global monitoring of the exis-
ence and functionality of NITAGs, WHO  and UNICEF included
uestions about NITAGs in the 2011WHO/UNICEF JRF [3]. The JRF
s a standardized questionnaire, developed by WHO  and UNICEF,
hat is sent annually to all Member States and provides an ofﬁcial
eans to collect data on immunization coverage, reported cases
f vaccine-preventable diseases, immunization schedules, among
ther indicators on immunization programme performance [6].
hile there are more comprehensive set of indicators developed
o assess NITAGs, a set of six process indicators was  selected for
nclusion in the JRF to allow for global monitoring of progress [7].
In 2012, we reported on the introduction of a monitoring process
or the establishment and strengthening of NITAGs and provided a
lobal status report for 2010 data [3]. The purpose of this paper is
o present the 2012 status of NITAGs based on the analysis of the
RF NITAG indicators and to review progress since 2010.
.  MethodsData for this paper were compiled from the 2011, 2012 and 2013
RF which collect data representing the country situation by end of
010, 2011, and 2012, respectively.ntries  advisory  groups.
3 The Authors. Published by Elsevier Ltd. 
Questions relating to NITAGs included a query on the existence
of a NITAG and a set of six process indicators pertaining to the
characteristics and functioning of the NITAG:
1. Legislative or administrative basis for the advisory group.
2. Formal written Terms of Reference.
3.  Diverse expertise/representation among core members (in
terms  of paediatrics, public health, infectious diseases, epidemi-
ology,  immunology or other health-care professionals).
4.  Number of meetings per year.
5.  Circulation of the agenda and background documents at least
one  week prior to meetings.
6. Mandatory disclosure of any conﬂict of interest.
More speciﬁc information on the JRF and the data collection
process was  previously published for 2010 data [3].
The  denominator used to calculate the proportion of NITAGs in
existence was the number of countries that completed the NITAG-
related section of the 2013 JRF. For countries indicating existence
of NITAGs, there was further analysis of the six NITAG process indi-
cators.
The results were stratiﬁed by WHO  regions (see Fig. 1) [8],
development status [9] and World Bank national income status
categories [10], eligibility for funding by the GAVI Alliance which
includes all countries with less than, or equal to, US$ 1520 of Gross
National Income (GNI) per capita in accordance with World Bank
data for the latest available year [11], and population size. Popula-
tion ﬁgures used are those from the UN population division [12].
3.  Results
By 15 August 2013, 188 of 194 (97%) Member States had com-
pleted the 2013 JRF,9 data for 2012 and 183 (94%)10 provided a
response to at least one of the NITAG-related questions of the JRF.
Among the countries that did not report their JRF or their JRF
data for 2012, Cape Verde, Finland, Marshall Islands, Russian Feder-
ation, the former Yugoslav Republic of Macedonia, Turkey, Ukraine
and the USA had reported last year NITAG data. The data for 2011
was included in the 2012 data set for these countries. Therefore,
data for 191 Member States was available for the analysis.
Table 1 presents the 2012 status of the NITAG-related indicators
at the global and at the regional levels.
Fig. 2 presents the distribution of countries according to the
reported existence of a NITAG with a legislative or administrative
basis.
Table 2 presents the analysis of the NITAG-related indicators
stratiﬁed by development status, World Bank income groups, eligi-
bility for ﬁnancial support from the GAVI Alliance and population
Open access under CC BY-NC-ND license.9 The Member States who have yet to submit a 2013 JRF include Austria, Cape
Verde,  Finland, Monaco, the former Yugoslav Republic of Macedonia and Turkey.
10 Member States that have not completed the NITAG portion of JRF include Mar-
shall  Islands, Russian Federation, Serbia, Ukraine and USA.
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Table 1
Analysis of the NITAG 2013 JRF, data for 2012 at global level and by WHO  region.
Region
Countries reporting/WHO Member States Indicator OVER ALL
N  = 191/194 (98%)
AFR N = 46/46
(100%)
AMR N = 35/35
(100%)
EMR N = 22/22
(100%)
EUR N = 50/53
(94%)
SEAR N = 11/11
(100%)
WPR N = 27/27
(100%)
Existence of a NITAG Number of countries 116 13 19 21 38 10 15
% of countries which responded 61% 28% 54% 95% 76% 91% 56%
% of the entire population covered 89% 57% 91% 98% 67% 99.9% 99%
Existence  of a NITAG with formal terms of
reference
Number of countries 104 12 15 20 35 10 12
% of countries reporting the existence of a
NITAG
90% 92% 79% 95% 92% 100% 80%
% of countries which responded 54% 26% 43% 91% 70% 91% 44%
Existence  of a NITAG with a legislative or
administrative basis
Number of countries 99 10 15 19 35 9 11
% of countries reporting the existence of a
NITAG
85% 77% 79% 90% 92% 90% 73%
% of reporting countries 52% 22% 43% 86% 70% 82% 41%
% of the entire population covered 85% 43% 90% 96% 65% 97% 98%
Existence  of a NITAG with >= ﬁve areas of
expertise represented
Number of countries 106 10 17 20 36 10 13
% of countries reporting the existence of a
NITAG
91% 77% 89% 95% 95% 100% 87%
Existence  of a NITAG which met  at least
once in 2012
Number of countries 103 12 16 18 38 8 11
% of countries reporting the existence of a
NITAG
89% 92% 84% 86% 100% 80% 73%
Existence  of a NITAG for which the agenda
and background documents distributed
>= one week prior to meetings
Number of countries 104 10 18 19 36 10 11
% of countries reporting the existence of a
NITAG
90% 77% 95% 90% 95% 100% 73%
Existence  of a NITAG whose members
required to disclose conﬂict of interest
Number  of countries 76 6 13 15 24 7 11
% of countries reporting the existence of a
NITAG
66% 46% 68% 71% 63% 70% 73%
Existence  of a NITAG meeting all six
criteria above
Number of countries 63 3 13 13 22 5 7
% of countries reporting the existence of a
NITAG
54% 23% 68% 62% 58% 50% 47%
% of reporting countries 33% 7% 37% 59% 44% 45% 26%
% of the entire population covered 52% 7% 88% 83% 41% 20% 81%
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Fig. 1. WHO  regions as of March 2012.
Fig. 2. National Immunization Technical Advisory Groups (NITAGs) in 2011 by WHO  regions.
5318 P.  Duclos et al. / Vaccine 31
Ta
b
le
 
2
A
n
al
ys
is
 
of
 
th
e  
N
IT
A
G
 
20
13
 
JR
F,
 
d
at
a 
fo
r 
20
12
 
by
 
d
ev
el
op
m
en
t 
st
at
u
s,
 
W
or
ld
 
B
an
k 
in
co
m
e 
st
at
u
s,
 
G
A
V
I A
ll
ia
n
ce
 
el
ig
ib
il
it
y,
 
an
d
 
p
op
u
la
ti
on
 
si
ze
.
D
ev
el
op
m
en
t  
St
at
u
s  
[7
]
W
B
 
In
co
m
e  
St
at
u
s  
[8
]a
G
A
V
I  E
li
gi
bl
e
C
ou
n
tr
ie
s 
[9
]
Po
p
u
la
ti
on
 
Si
ze
 
[1
0]
Le
as
t
d
ev
el
op
ed
Ec
on
om
y  
in
tr
an
si
ti
on
D
ev
el
op
in
g  
D
ev
el
op
ed
ec
on
om
y
Lo
w
in
co
m
e
M
id
d
le
in
co
m
e
H
ig
h
in
co
m
e
Le
ss
 
th
an
7,
78
9,
87
6b
G
re
at
er
 
th
an
 
or
 
eq
u
al
to
 
7,
78
9,
87
6
R
ep
or
ti
n
g  
C
ou
n
tr
ie
s  
To
ta
l
49
/4
9 
(1
00
%
)
17
/1
8  
(9
4%
)
89
/8
9  
(1
00
%
)
36
/3
8  
(9
5%
)
36
/3
6  
(1
00
%
)
99
/1
00
 
(9
9%
) 
53
/5
5 
(9
6%
) 
57
/5
7 
(1
00
%
) 
96
/9
7 
(9
9%
) 
95
/9
7 
(9
8%
)
N
IT
A
G
 
To
ta
l/
N
o.
 
re
p
or
ti
n
g  
(%
)
18
/4
9 
(3
7%
)
10
/1
7  
(5
9%
)
57
/8
9  
(6
4%
)
31
/3
6  
(8
6%
)
13
/3
6  
(3
6%
)
62
/9
9  
(6
3%
)
41
/5
3  
(7
7%
)
26
/5
7  
(4
6%
)
50
/9
6  
(5
2%
)
66
/9
5  
(6
9%
)
Fo
rm
al
 
te
rm
s  
of
 
re
fe
re
n
ce
/N
o.
re
p
or
ti
n
g 
(%
)
17
/4
9  
(3
5%
)
9/
17
 
(5
3%
)
49
/8
9  
(5
5%
) 
29
/3
6 
(8
1%
) 
13
/3
6 
(3
6%
) 
53
/9
9 
(5
4%
) 
38
/5
3 
(7
2%
) 
25
/5
7 
(4
4%
) 
42
/9
6 
(4
4%
) 
62
/9
5 
(6
5%
)
Le
gi
sl
at
iv
e 
or
 
ad
m
in
is
tr
at
iv
e 
ba
si
s 
fo
r
N
IT
A
G
/N
o.
 
re
p
or
ti
n
g  
(%
)
13
/4
9  
(2
7%
) 
9/
17
 
(5
3%
) 
48
/8
9 
(5
4%
) 
29
/3
6 
(8
1%
) 
10
/3
6 
(2
8%
) 
50
/9
9 
(5
1%
) 
39
/5
3 
(7
4%
) 
21
/5
7 
(3
7%
) 
39
/9
6 
(4
1%
) 
60
/9
5 
(6
3%
)
A
t 
le
as
t  
ﬁ
ve
 
ar
ea
s  
of
 
ex
p
er
ti
se
re
p
re
se
n
te
d
/N
o.
 
re
p
or
ti
n
g  
(%
)
14
/4
9  
(2
9%
)
10
/1
7  
(5
9%
)
53
/8
9  
(6
0%
)
29
/3
6  
(8
1%
)
9/
36
 
(2
5%
)
59
/9
9  
(6
0%
)
38
/5
3  
(7
2%
)
21
/5
7  
(3
7%
)
45
/9
6  
(4
7%
)
61
/9
5  
(6
4%
)
M
et
 
at
 
le
as
t  
on
ce
 
in
 
20
12
/N
o.
 
re
p
or
ti
n
g
(%
)
12
/4
9 
(2
4%
)
10
/1
7  
(5
9%
)
50
/8
9  
(5
6%
)
31
/3
6  
(8
6%
)
10
/3
6  
(2
8%
)
53
/9
9  
(5
4%
)
40
/5
3  
(7
5%
)
20
/5
7  
(3
5%
)
42
/9
6  
(4
4%
)
61
/9
5  
(6
4%
)
A
ge
n
d
a  
an
d
 
ba
ck
gr
ou
n
d
 
d
oc
u
m
en
ts
d
is
tr
ib
u
te
d 
on
e  
w
ee
k  
p
ri
or
 
to
m
ee
ti
n
gs
/N
o.
 
re
p
or
ti
n
g  
(%
)
14
/4
9  
(2
9%
)
9/
17
 
(5
3%
)
52
/8
9  
(5
8%
)
29
/3
6  
(8
1%
)
11
/3
6  
(3
1%
)
53
/9
9  
(5
4%
)
40
/5
3  
(7
5%
)
22
/5
7  
(3
9%
)
44
/9
6  
(4
6%
) 
60
/9
5 
(6
3%
)
R
eq
u
ir
ed
 
to
 
d
is
cl
os
e  
co
n
ﬂ
ic
t  
of
in
te
re
st
/N
o.
 
re
p
or
ti
n
g 
(%
)
11
/4
9  
(2
2%
)
3/
17
 
(1
8%
)
37
/8
9  
(4
2%
)
25
/3
6  
(6
9%
)
7/
36
 
(1
9%
)
36
/9
9  
(3
6%
)
33
/5
3  
(6
2%
)
13
/5
7  
(2
3%
)
26
/9
6  
(2
7%
)
50
/9
5  
(5
3%
)
M
ee
ti
n
g  
al
l s
ix
 
cr
it
er
ia
 
ab
ov
e/
N
o.
re
p
or
ti
n
g 
(%
)
6/
49
 
(1
2%
) 
3/
17
 
(1
8%
) 
32
/8
9 
(3
6%
) 
22
/3
6 
(6
1%
) 
4/
36
 
(1
1%
) 
29
/9
9 
(2
9%
) 
30
/5
3 
(5
7%
) 
9/
57
 
(1
6%
) 
22
/9
6 
(2
3%
) 
41
/9
5 
(4
3%
)
a
Th
e  
d
en
om
in
at
or
 
is
 
n
ot
 
th
e  
19
4  
W
H
O
 
M
em
be
r  
St
at
es
, b
u
t 
19
1 
co
u
n
tr
ie
s 
fo
r 
w
h
ic
h
 
th
e 
W
or
ld
 
B
an
k 
is
 
p
ro
vi
d
in
g 
th
e 
in
fo
rm
at
io
n
, a
s 
of
 
Ju
ly
 
20
13
. I
n
fo
rm
at
io
n
 
on
 
st
at
u
s 
is
 
m
is
si
n
g 
fo
r 
th
e 
C
oo
k 
Is
la
n
d
s,
 
N
au
ru
, a
n
d
 
N
iu
e.
b
Th
is
 
ﬁ
gu
re
 
w
as
 
se
le
ct
ed
 
as
 
be
in
g 
th
e 
m
ed
ia
n
 
of
 
th
e 
to
ta
l p
op
u
la
ti
on
 
fo
r 
th
e 
19
4 
W
H
O
 
M
em
be
r 
St
at
es
. (2013) 5314– 5320
formal legislative or administrative basis and 104 (54%) countries
reported the existence of a NITAG with formal terms of reference.
In 2012, there were 63 countries (33%) with a NITAG that met  all six
process indicators11 (a 5% increase from the 43 in countries with a
NITAG that met  all six process indicators in 2010 and an absolute
46% in the number of countries that met  the 6 process indicators –
in a 2008 global survey using a different methodology and with a
lower response rate only 23 countries had indicated the existence of
a NITAG that met  6 fairly similar indicators [3]) including a total of
38 developing countries. Eleven percent of low-income countries,
29% of middle-income countries, and 57% of high-income countries
reported having a NITAG meeting all six process criteria. Overall,
85% of the total global population lives in a country served by a
NITAG with a formal legislative or administrative basis including
52% who  live in a country with a NITAG that meets all six process
indicators. Twenty-three percent of countries with smaller popu-
lations (less than the median population of WHO  member States)
reported the existence of a NITAG that meets all six process indica-
tors, compared with 43% of more populated countries.
EMR  had the highest proportion of countries reporting the exis-
tence of a NITAG that met  all six process indicators (59%) and AFR
the lowest (7%). EMR  had also the greatest percentage (86%) of
countries that had a NITAG based on a formal legislative decree
(22% in AFR, 41% in WPR, 43% in AMR  (both regions affected by
number of small countries), 70% in EUR, and 82% in SEAR).
For  countries reporting the existence of a NITAG, 106 (91%) had
at least ﬁve areas of expertise represented in the group’s core mem-
bership during 2012. The areas of expertise most frequently cited
included: public health [111 (96%) countries]; epidemiology [107
(92%) countries]; paediatrics [112 (97%) countries]; infectious dis-
eases [112 (97%) countries], and immunology [86 (74%) countries].
Other speciﬁc areas of expertise were represented in 92 (79%) of
the committees as part of core membership.12
One hundred and three (89%) NITAGs met  at least once during
2012 with a mode of two and a median of four meetings a year
(range: 1 to 40 and in 85% of cases the group met  ﬁve times or less
a year). The agenda and background documents for meetings are
reported to be circulated one week or more prior to the meetings
for 104 (90%) NITAGs. Members are required to declare any conﬂict
of interest for 76 (66%) NITAGs.
4. Discussion
As highlighted in a previous report [1] and despite the very high
response rate, results are subject to some limitations. First, some
countries did not provide answers to the NITAG-related questions
in the most recent JRF, and there is some variation among the coun-
tries that provided answers to the NITAG-related questions for the
11 Afghanistan, Andorra, Argentina, Australia, Bahrain, Belgium, Bhutan, Bosnia
and  Herzegovina, Brazil, Canada, Chile, China, Colombia, Côte d’Ivoire, Cuba, the
Czech Republic, Democratic People’s Republic of Korea, Denmark, Egypt, El Salvador,
Estonia, France, Germany, Honduras, Iceland, Indonesia, Iran (Islamic Republic of),
Ireland, Israel, Jordan, Kazakhstan, Lithuania, Luxembourg, Malaysia, Malta, Mexico,
Mongolia, Morocco, Mozambique, Nepal, the Netherlands, New Zealand, Oman,
Pakistan,  Panama, Peru, Portugal, Qatar, Republic of Korea, Romania, Saudi Ara-
bia, Singapore, Slovakia, the Sudan, Switzerland, the Syrian Arab Republic, Thailand,
Tunisia, the United Kingdom of Great Britain, the United States of America, Uruguay,
Uzbekistan  and Zambia.
12 Other areas of expertise mentioned included: vaccinology; family medicine; car-
diology; neurology – including paediatric neurology; internal medicine; hepatology;
travel medicine; neonatology; pneumo-phtysiology; gynaecology; school-health;
microbiology  including virology; health-service delivery and immunization pro-
gramme management. The following professional categories were also included in
some of the NITAGs: health economists; mathematical modellers; nurses; phar-
macists; logisticians; vaccine procurement; vaccine safety specialists; programme
planners;  research scientists; communication specialists; lawyers; ethicists; drug
regulators; data managers; and laboratory technicians.
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012 JRF and the 2013 JRF. Further the list of countries/member
tates  is not totally stable and in 2011 South Sudan became a new
ember state located in the EMR  WHO  region. Second, because
he analysis focused on data ofﬁcially reported by the countries,
ithout a systematic secondary validation process with national
ounterparts (although this is done in some regions), it may  not
eﬂect the actual situation in the countries. Data accuracy depends
n the knowledge, recollection and interpretation capabilities of
he person completing the form; since the introduction of the
ITAG-related questions in the JRF is still relatively recent, it is
ossible that some questions may  have been misunderstood or mis-
nterpreted. For example, in some regions an afﬁrmative answer
egarding the existence of a NITAG may  have actually referred
o an Inter-agency Coordinating Committee (ICC), a committee
hat coordinates and supports funding, planning, implementation
nd advocacy [3]. In the 2013 and 2012 JRF, 7 African countries
Benin, Cameroon, Central African Republic, Gambia, Madagascar,
iger and Senegal) explicitly indicated having previously reported
he existence of an Inter-agency Coordinating Committee versus
 NITAG. As a result it is likely that data for 2012 are more reli-
ble than those from previous years and comparison with previous
ears has therefore to be taken in this context.
Overall, 54% of countries reported the existence of a NITAG with
ormal terms of reference, and 52% reported the existence of a
ITAG with a formal administrative or legislative basis. These data
hould be less susceptible to reporting bias, and therefore closest
o the actual number with respect to the existence of a NITAG. In
urn the number of countries reporting the existence of a NITAG
hich complies with all 6 JRF indicators is also less susceptible to
eporting bias.
Some  of the countries rightly reported the existence of a NITAG
ven if the mandate of the committee was broader than focusing on
mmunization e.g. extended mandate for broader infectious disease
ontrol.
Despite the short period of time and considering that establish-
ng and strengthening NITAGs is a long term process, there seems
o have been a constant progress in regards to the establishment of
ITAGs over the last couple years. Globally, by the end of 2012 here
ere 63 NITAGs afﬁrmative about the six NITAG process indicators,
ompared with 56 and 43 for 2011 and 2010 respectively. However,
here continues to be opportunity and need for more progress for
trengthening NITAGs as called for by the GVAP. The GVAP repre-
ents an important opportunity to accelerate the establishment of
ITAGs and continue strengthening the capacity of existing NITAGs.
Because the proportion of countries with a NITAG is greater in
he more populous countries than in the less populous ones, the
verall proportion of the population supported by a NITAG is sub-
tantially greater than the proportion of counties with a NITAG,
oth at the global and regional levels. If one looks further at the
roportion of population covered by a NITAG meeting all six pro-
ess indicators, then the Americas ranks ﬁrst among all six regions,
ith 88% of its population covered and EMR  ranks second with 83%
f its population covered.
In  areas where regional engagement has been strong and there
ave been strong regional TAG statements with regard to the need
o strengthen NITAGs such as in AMR, EMR, EUR and SEAR rapid
rogress is being achieved. The participation of NITAG chairs at
mmunization and regional TAG meeting has been in most regions
ogether with fostering of exchanges between NITAGs have been
eceived very positively by all and can contribute to emulating
rogress.
Beyond progress on meeting the indicator there has been sub-
tantial quality improvement in the processes of many NITAGs
hich are hard to quantify at global level but worth highlighting.
Despite  this progress, efforts need to be accelerated to reach
he GVAP target of ensuring that all countries have the support of (2013) 5314– 5320 5319
a  NITAG. Such progress is particularly necessary in the AFR and
WPR regions. Essential to progress is the need for concerted advo-
cacy from all partners, including clear communication about the
difference responsibilities of NITAGs and ICCs. Systematic com-
munication and advocacy from all partners in support of NITAG
strengthening. In this context it should be clear that introduction
of new vaccines in a country does not in any way  diminish the need
for the establishment/strengthening of NITAGs. Very limited ﬁnan-
cial support to help provide technical support to middle income
countries has hampered progress.
Requiring the existence of NITAGs for future funding applica-
tions from GAVI-eligible countries and communicating about the
possibility of accessing GAVI’s Heath System Strengthening funds
to establish and strengthen NITAGs may  be desirable.
A special approach needs to be explored to allow small countries
to beneﬁt from sub-regional or other countries advisory groups.
Small countries, including some of the Caribbean islands, small
island nations in the Western Paciﬁc region, and some other small
countries, may  not have a large enough population to justify estab-
lishment of a NITAG and/or adequate resources to support its
establishment. Some of these less populated countries, particularly
those in close geographical proximity and which share cultural
similarities, similar epidemiologic proﬁles, or have a tradition of
working together on public health issues, may choose to seek guid-
ance from a subregional decision-making mechanism, such as the
former Caribbean Epidemiology Centre (now the Caribbean Public
Health Agency) or Caribbean EPI Managers Meeting. Such discus-
sions have started in the Americas for the Caribbean and in WPR
for the Paciﬁc Islands.
Current  challenges to the establishment of NITAGs include the
need to ensure adequate expertise, independence from the gov-
ernment, transparency of the process, and quality review of the
evidence on which recommendations are based. Meeting the 6
basic process indicators is the ﬁrst step, and committees that meet
with these criteria should continue to be strengthened. Foster-
ing exchanges between NITAGs is an important way  to facilitate
support and progress. These exchanges should extend to making
evidence available to other groups, such as public posting of sys-
tematic reviews. Very limited resources are available from partners
to support NITAG strengthening in middle income countries, high-
lighting the need for these countries to capitalize on initiatives such
as SIVAC and ProVac. Efforts to establish NITAGs through profes-
sional organizations such as academies of paediatrics need to be
well-coordinated with the government, to ensure that there is not
a development of parallel groups.
Exploring the potential transition from polio or other VPD-
speciﬁc technical advisory groups (TAGs) where they exist, to
NITAGs, is an important consideration.
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